Clinical Trial Update: TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating transarterial chemoembolization combined with tyrosine kinase inhibitors and tislelizumab in unresectable hepatocellular carcinoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Guangxi Medical University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED